Kornimate/medical-research-clean huggingface dataset:
comprehensive genomic analysis in tissue and blood samples from young patients with lung cancer

Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer

Summary: this research trial studies genomic analysis in tissue and blood samples from young patients with lung cancer. identifying specific gene mutations (changes in deoxyribonucleic acid \[dna\]) may help doctors tailor treatment to target the specific mutations and help plan effective treatment.

primary objectives: i. to perform comprehensive genomic analysis of young lung cancer patients' samples to facilitate delivery of targeted therapies and clinical trial enrollment. ii. to characterize the impact of young age at lung cancer diagnosis on the genomic landscape of primary lung cancer. iii. to establish a prospective registry of young lung cancer patients for both tumor and germline next generation sequencing. outline: tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing. after completion of study, patients are followed up every 3 months for up to 3 years.

Eligibility criteria:
inclusion criteria: * cohort 1: lung cancer patients * pathologically confirmed bronchogenic lung carcinoma (small cell lung cancer \[sclc\] or non-small cell lung cancer \[nsclc\] of any stage) at any treatment time point * for individuals diagnosed with advanced disease (stage iv or recurrent) enrollment must occur within 2 years of diagnosis * for appropriate patients (stage iv non-squamous nsclc) epidermal growth factor receptor (egfr ) and anaplastic lymphoma kinase (alk) genotyping performed by a clinical laboratory improvement amendments (clia) certified laboratory is recommended prior to participation * provision of written informed consent * willingness to undergo a single blood draw * individuals who are under 18 are eligible for study if they meet the defined criteria for cohort 1; in addition, consent for participation must be given by a legal guardian or parent * note: to be eligible for genomics, availability of 10 unstained slides (plus hematoxylin and eosin \[h\&e\] slide) or an adequate formalin-fixed paraffin-embedded (ffpe) tumor block from clinically indicated interventional procedures is required * cohort 2: deceased individuals * deceased individuals diagnosed with lung cancer at any age less than 40 may be studied on a case by case basis depending upon institutional review board (irb) approval at a participating institution; inclusion will require availability of adequate archived ffpe tissue and release of tissue and records by next of kin, if available exclusion criteria: * compromise of patient diagnosis or staging if tissue is used for research
biobehavioral intervention in gynecologic oncology patients

Conditions: Neoplasms; Ovarian Neoplasms; Uterine Neoplasms; Vulva

Summary: baseline self-report outcome measures will be completed and additional assessments will occur mid-treatment , post-treatment , 3 months following completion of all sessions, and 6 months following completion of all sessions. patients and therapists will complete the evaluation measures in private (at home, in an office). at the university of kentucky markey cancer center, bbi treatment is offered in group and individual formats. the course of individual treatment varies and group treatment consists of 10 1.5-hour weekly sessions in the "intensive" phase, followed by 2 1.5-hour bi-weekly maintenance sessions. individual treatment is one-on-one. in group treatment, there are typically 6-12 patients per group and 1 or 2 therapists. the intervention helps patients to learn adaptive coping strategies and how to apply them to daily stressors. additional content discusses use of seeking information, enhancing social support, enhancing body esteem and intimacy, and maintaining positive changes.


Eligibility criteria:
inclusion criteria: * females * stage i-iv gynecologic cancer (including ovarian, uterine, cervical, vulvar, or vaginal cancer) * undergoing active treatment or in remission and undergoing active surveillance; age ≥21 and ≤80 * able to speak/read english. exclusion criteria: * concurrent diagnosis of organic brain syndrome, dementia, mental retardation * non-english speaking, or significant sensory deficit * major mental illness (e.g., schizophrenia, psychotic disorder).
optical stimulation in peripheral nerves for select rhizotomy procedures

Conditions: Spasticity

Summary: the purpose of this study is to determine the safe and effective levels of optical stimulation in peripheral nerves of humans otherwise undergoing nerve lesioning in surgery.

the purpose of this study is to determine the safe and effective levels of optical stimulation in peripheral nerves of humans otherwise undergoing nerve lesioning in surgery, namely children undergoing selective rhizotomy for treatment of medically refractory spasticity.

Eligibility criteria:
inclusion criteria: * children over the age of 3 and younger than 17 years * children who have failed appropriate medical therapy and are recommended for selective rhizotomy to treat spasticity by the pediatric neurosurgeon * children who would normally undergo electrodiagnostic testing including emg monitoring for physiologic testing during surgery * surgery must be performed at the vanderbilt university children's hospital exclusion criteria: * patients in which a segment of the nerve (up to 2cm) cannot likely be identified at the time of surgery as determined by the pediatric neurosurgeon * children not undergoing routine selective rhizotomy for medically refractory spasticity as determined by the pediatric neurosurgeon * children who are medically unstable to tolerate an additional 20 minutes of experimental testing during the surgery * women who are pregnant will be excluded from this study

Keywords: spasticity rhizotomy surgery
strategic management to improve crt using multi-site pacing post approval study (reference # c1918)

Conditions: Left Ventricular Dysfunction

Summary: prospective, multi-center, single arm, post approval study to be conducted in the united states.

evaluate the effectiveness of boston scientific (bsc)'s lv msp (left ventricular multisite pacing) feature in the resonate family of crt-d devices and confirm safety in a post approval study when used in accordance with its approved labeling.

Eligibility criteria:
inclusion criteria: 1. subjects who received de novo implantation of bsc's resonate family of crt-d devices with the lv msp feature4 and bsc's acuitytm x4 lv quadripolar leads. a resonate family of crt-d device upgrade from previous single or dual chamber pacemaker or icd implantation is allowed. 2. subjects must meet bsc labeled indication for crt-d implantation. 3. subjects must have a functional ra lead and rv lead implanted 4. subjects who are willing and capable of providing informed consent 5. subjects who are willing and capable of participating in all testing/visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol 6. subjects who are age 18 and above, or of legal age to give informed consent specific to state and national law exclusion criteria: 1. subjects who received lv pacing prior to receiving the resonate family of crt-d system implantation. 2. subjects who received the lv msp therapy post crt-d implantation but prior to enrollment 3. subjects with documented history of permanent af 4. subjects with documented permanent complete av block 5. subjects who are expected to receive a heart transplant during the 12 months course of the study 6. subjects with documented life expectancy of less than 12 months 7. subjects who enrolled in any other concurrent study or registry, with the exception of mandatory national or governmental registry, without prior written approval from bsc

Keywords: pacing
neuropsychological prognosis factors of smoking cessation

Conditions: Smoking Cessation; Nicotine Dependence

Summary: the low overall effectiveness of available smoking cessation treatment so far, indicate the need for new and more efficacious ways to help smokers maintain abstinence. smokers are a highly heterogeneous population. identification of individual characteristics that predict success in smoking cessation is highly desirable to allow designing more specific strategies in order to enhance success in quitting tobacco.the main objective of this study is to assess whether the presence of certain neuropsychological deficits found before the initiation of smoking cessation is associated with a greater relapse rate.the secondary objectives concern how neuropsychological performance are involved in motivation and craving in the whole sample of smokers or in subsample. long-term perspective is to define clinical or neuropsychological factors associated with agood or poor prognosis for success and provived more specific and therefore more effective care.

this is a prospective multicenter study. patients will be recruited to anti tobacco consultations in the montpellier and clermont-ferrand university hospitals. the initial assessment includes a clinical assessment of smoking history, axis i disorders history, motivation to quit and craving, a neuropsychological assessment : nart, rvip task, trail making test, stroop, iowa gambling task, hayling test, n back, verbal fluency. then patients will be reviewed 3 times in 6 months. these visits include: co level and cigarette consumption since the last visit, cessation strategy (medication, observance ... ), tobacco craving questionnary, withdrawal symptoms, abstinence. the primary endpoint will be smoking abstinence objectified by the rate of carbon monoxide measured at each visit. subjects who emerge from the study prematurely, especially patients lost to follow will be considered as failures in the statistical analysis.

Eligibility criteria:
inclusion criteria: * men and women aged 18-60 years old * patient applying for withdrawal regardless of the number of p / a, the length of smoking. * patient with nicotine dependence (fagerstrom test score \> or = 3) * patient able to understand the nature, purpose and methodology of the study * patient who gave written informed consent to participate in the study * patient agree to cooperate in the clinical and neuropsychological evaluation * patient affiliated to a french social security system exclusion criteria: * patient with a physical disease being able to interact with the cognitive performances: dysthyroidies, pituitary adenomas, neurodegenerative diseases, parkinson's disease, neoplastic diseases with intellectual location, the central neurological disorders, the cranial traumas. * patient in the incapacity to answer at neuropsychological tests * patient who can't go back at visits in 6 months * pregnancy women

Keywords: smoking neuropsychology abstinence prognosis nicotine dependence, cigarettes, with other nicotine-induced disorders
mobilisation and breathing exercises after abdominal surgery at sahlgrenska university hospital

Conditions: Abdominal Surgery

Summary: the aim of the study is to evaluate the effect of a new care strategy, including earlier and more intensive mobilization and individually adapted breathing exercises, regarding length of stay, recovery, complications and which factors predict interventions early in the postoperative course after various abdominal surgical procedures.


Eligibility criteria:
inclusion criteria: * undergoing elective or emergency open, or robot-assisted abdominal surgery * has an expected anesthesia time of over 4 hours * is extubated on the operating table * planned overnight stay in the postoperative ward. exclusion criteria: * plastic, trauma, transplant or orthopedic surgery.
swiss primary sclerosing cholangitis cohort study

Conditions: Cholangitis, Sclerosing

Summary: research project in which biological material is sampled and health-related personal data is further used and collected. coded data are used.

the investigators wish to collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome. in addition, a biobank allows addressing specific scientific issues on a variety of open questions. the cohort will provide a platform for carrying out scientific research projects on psc. in addition, the cohort will allow collaborations with reference networks on psc abroad

Eligibility criteria:
inclusion criteria: * patients diagnosed with psc according to established criteria (european association for the study of the liver. easl clinical practice guidelines: management of cholestatic liver diseases) of any age. patients not fulfilling such criteria but still diagnosed with psc in a hepatology referral centre can be included * patients living in switzerland exclusion criteria: * n/a
the survival outcome of adjuvant chemotherapy for stage i pancreatic cancer

Conditions: Pancreas Cancer; Chemotherapy

Summary: this study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with stage i pancreatic cancer stratified by pathologic risk factors.


Eligibility criteria:
inclusion criteria: patients who underwent surgical resection and were pathologically diagnosed as pdac between 2010 and 2021. - exclusion criteria: patients with pn1-n2, patients with pt3-t4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with r1 resection, and patients who died due to perioperative mortality within 30 days. -
neutrophil oxidative burst in early and late onset pediatric inflammatory bowel disease

Conditions: Chronic Granulomatous Disease

Summary: abstract introduction residual or absent oxidase function in peripheral neutrophils may point to an inborn defect of neutrophil function - chronic granulomatous disease (cgd) - whereas low to normal oxidative burst capacity has been linked to variants in various members of the nadph-complex. aims to assess the clinical value of routinely measuring oxidative burst activity of granulocytes in pediatric patients diagnosed with very early onset ibd (veo-ibd) and late onset ibd. objectives to investigate possible correlations between neutrophil function and ibd disease activity and to inquire the presence of genetic variants in those with low to absent oxidative burst. to identify the rate of monogenic veo-ibd in our cohort. materials and methods the proposal constitutes a collaborative effort among romanian pediatric tertiary care centers to examine the value of assessing neutrophil function in all pediatric ibd patients. children aged \<18 years diagnosed with crohn's disease, ulcerative colitis or ibd-undetermined and age-matched healthy controls are recruited. a dhr flow cytometry assay is performed in included subjects and controls. reduced or absent burst activity will lead to genetic testing in search of overt immunodeficiency or susceptibility variants. all veo-ibd patients will have an immunological work-up in search of a primary immunodeficiency. expected results we anticipate to include a number of 150 pediatric patients with ibd over 12 months from the three pediatric gastroenterology units in bucharest, romania. we expect to identify an overall diminished neutrophil function in ibd patients versus controls and possible variants in the nadph-complex genes.


Eligibility criteria:
inclusion criteria: subjects: 1. age under 18 years; 2. confirmed diagnosis of ibd fulfilling standard diagnosis criteria (clinical, radiological, endoscopical, histological features) 3. parental/guardian consent for study enrollment controls: healthy age-gender matched controls exclusion criteria: 1. ibd associated to an already defined monogenic defect 2. diagnosis of ibd uncertain 3. hiv/tb positive

Keywords: inflammatory bowel disease chronic granulomatous disease inborn errors of immunity
prevalence of masked hypertension in nephrological patients

Conditions: Masked Hypertension

Summary: the purpose of this study is to determine the percentage of patients with masked hypertension in a population with chronic kidney disease. the investigators goal is to register prospectively ambulatory blood pressure measurement results of patients of a nephrological outpatient clinic with normal office blood pressure to finally find the percentage of masked hypertension in this population.


Eligibility criteria:
inclusion criteria: * age: 20-90 years * known arterial hypertension and antihypertensive medical treatment * office blood pressure \< 140 mmhg systolic and \<90 mmhg diastolic exclusion criteria: * age \ 90 years

Keywords: masked hypertension, chronic kidney disease
use of a connected companion in children with cystic fibrosis

Conditions: Cystic Fibrosis in Children; Chronic Disease

Summary: the study will be conducted over a 6 months period. for the first three months, the child will be accompagned with a connected companion. after this period, the companion will be removed for three months in oder to prove this companion could improve treatment adherence for children suffering from cytolisis fibrosis. this study will be conducted at the university hospital center of rennes and hospital center of saint-brieuc.

in developed countries, chronic diseases with long-term therapy adherence is about 50%, according to the who report, and the adherence rate for regular intake of preventive therapies decreases to 28%. for cystic fibrosis, rates are not much higher. optimistic articles report an average compliance rate of 60%. other articles report a rate of 50% which varies according to the age of the patient, the intake treatment complexity and burdensome drug treatment (physiotherapy achieves the lowest adherence with 38%), the disease understanding and the interest of treatment persuasion. low adherence can also be the result of incorrect use of administration devices, for example for inhaled treatments. technical errors are very frequent and affect around 30% of patients. families with children suffering from cystic fibrosis need daily support. health professionals need to relay their recommendations at home. this is why new and funny tools dedicated to children with chronic illnesses are needed. this trial will study the impact of connected companion named leo® created by ludocare company. study will be conducted as : * v0 : companion given to the child * v1 : companion removed after 3 months of use * v2 : follow-up done between 1 and 3 months after the period without companion

Eligibility criteria:
inclusion criteria: * child volunteer from 3 to 11 years old * affected by cystic fibrosis * with a prescription containing at least two medications twice a day * affiliation to the national health insurance * child and holder of the exercise of parental authority understands and speaks french * the person exercising parental authority must have reached the age of majority. * collection of the written consent of one of the holders of the exercise of parental authority exclusion criteria: * non-voluntary child, under 3 years of age or over 12 years of age * family reluctant to technology * family without smartphone and/or wifi connection * failure to obtain the written consent of one of the holders of the exercise of parental authority * child involved in research involving the human person

Keywords: connected device long-term therapy pneumology adherence therapy pediatric research pediatric device support
lancovutide (moli1901) inhalation solution study in adolescents and adults with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this is a dose-finding study for the investigational product lancovutide (moli1901) in the exploratory phase iib to establish minimum effective dose, optimal dose, and maximum safe dose. additionally, the tolerability of moli1901 shall be investigated.

study moli1901-010b is a multi center, parallel group, placebo controlled, double-blind efficacy and safety evaluation of three different dosage schedules of aerosolized moli1901 in adolescents (12 years of age or older), and adults. study will start with a screening period (visit 1) followed by an 8 weeks double blind comparative treatment period (visit 2-7). thereafter, subjects will be observed for additional 4 weeks without treatment (follow-up period and visit 8). spirometry, pulse oximetry and other safety measurements will be performed up to 120 min after study medication inhalation. the study will be conducted in 30 sites in 9 european countries.

Eligibility criteria:
inclusion criteria: * body mass index * confirmed diagnosis of cystic fibrosis * fev1 between 50% and 85% of predicted * oxygen saturation level measured by pulse oximetry (spo2) \>90 % on room air exclusion criteria: * bronchial hyperresponsiveness * unstable lung function * pulmonary disease such as pneumonia, tuberculosis, or lung cancer * acute upper respiratory tract infection within the last 2 weeks * acute lower respiratory tract infection (requiring antibiotics or hospitalization) within the last 4 weeks * pulmonary exacerbation within the last 4 weeks * changes from routine maintenance therapy within the last 4 weeks * scheduled changes to inhaled antibiotics regimen during the course of the study * receive or are planned to receive any treatment via "on-off" regimen (e.g. tobramycin - tobi®); last dose of any "on-off" treatment within the last 6 weeks * any clinically significant liver, renal, cardiac, neurological, or hematological disease * abpa or colonization with burkholderia cepacia * poorly controlled diabetes mellitus

Keywords: cystic fibrosis moli1901 lancovutide 2622u90 duramycin lung
efficacy of web-based social-cognitive interventions in right hemisphere stroke and frontotemporal dementia

Conditions: Frontotemporal Dementia; Right Sided Cerebral Hemisphere Cerebrovascular Accident

Summary: this study is being done to test the feasibility and effectiveness of web-based social-cognitive training exercises in treating social-emotional deficits in patients with stroke or frontotemporal dementia (ftd).

although deficits in empathy and social interaction are relatively common in certain forms of ftd and stroke, there are currently no proven treatments for these symptoms. spouses and caregivers often cite these symptoms as a major concern, and these deficits can have a negative impact on the quality of life that patients experience. the purpose of this study is to evaluate whether or not web-based social training exercises can improve social-cognitive impairments in patients with ftd or right hemisphere stroke. these training exercises have been shown to improve social skills and empathy in other disorders. this study will be the first to examine if these exercises can be effective and feasible for treating social deficits in stroke and ftd. the study will be based out of the johns hopkins hospital where patients will be assessed three times in total. patients will be assessed upon enrollment in the study and after each of the two treatment conditions. the training itself will be completed at home on a provided laptop, with monitoring and support by the study team. this study uses a crossover design, which means that all patients will receive the training treatment and a control treatment during their participation in the study. the approximate timeline for the study is 9 weeks total.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of right hemispheric stroke or behavioral variant frontotemporal dementia. * able to give informed consent. * premorbid proficiency in english (by self-report). * age 18 or older. * score of 21 or higher on the mini-mental state examination. exclusion criteria: * prior history of neurological disease affecting the brain other than stroke or frontotemporal dementia (e.g., brain tumor, multiple sclerosis, traumatic brain injury) * known uncorrected hearing loss * known uncorrected vision loss * prior history of severe psychiatric illness, developmental disorders, or mental retardation (e.g., schizophrenia, autism spectrum disorders) other than ftd * score of 20 or lower on the mini-mental state examination.

Keywords: treatment social-cognitive training web-based right hemisphere stroke frontotemporal dementia right sided cerebral hemisphere cerebrovascular accident